Last reviewed 2026-04-20 · How we verify

Abrocitinib Suspension F6 (abrocitinib-suspension-f6)

Pfizer · FDA-approved active Quality 40/100

Abrocitinib Suspension F6 (generic name: abrocitinib-suspension-f6) is a JAK inhibitor drug developed by Pfizer. It is currently FDA-approved for Moderate to severe atopic dermatitis in adults, Moderate to severe atopic dermatitis in children 12 years of age and older.

Abrocitinib Suspension F6 is a marketed drug by Pfizer Inc. for moderate to severe atopic dermatitis in adults and children 12 years of age and older. It is a small molecule with a mechanism of action that targets the JAK1 enzyme. This drug has clinical differentiation due to its efficacy in treating atopic dermatitis. The commercial significance of Abrocitinib Suspension F6 is its high revenue of $21.2B. There are no pipeline developments mentioned. The drug's key indications are moderate to severe atopic dermatitis in adults and children 12 years of age and older.

At a glance

Generic name	abrocitinib-suspension-f6
Sponsor	Pfizer
Drug class	JAK inhibitor
Target	JAK1
Therapeutic area	Immunology
Phase	FDA-approved
Annual revenue	284

Approved indications

Moderate to severe atopic dermatitis in adults
Moderate to severe atopic dermatitis in children 12 years of age and older

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Live vaccines
Bacillus Calmette-Guérin (BCG) vaccine
Other vaccines
Interleukin-1 (IL-1) inhibitors
Live attenuated influenza vaccine
Tuberculosis vaccine
Vaccines
Vaccines (live)
Vaccines (live, attenuated)
Vaccines (live, attenuated, or inactivated)
Vaccines (live, attenuated, or inactivated; including inactivated influenza vaccine)

Key clinical trials

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Abrocitinib Suspension F6 CI brief — competitive landscape report
Abrocitinib Suspension F6 updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Abrocitinib Suspension F6

What is Abrocitinib Suspension F6?

Abrocitinib Suspension F6 (abrocitinib-suspension-f6) is a JAK inhibitor drug developed by Pfizer, indicated for Moderate to severe atopic dermatitis in adults, Moderate to severe atopic dermatitis in children 12 years of age and older.

What is Abrocitinib Suspension F6 used for?

Abrocitinib Suspension F6 is indicated for Moderate to severe atopic dermatitis in adults, Moderate to severe atopic dermatitis in children 12 years of age and older.

Who makes Abrocitinib Suspension F6?

Abrocitinib Suspension F6 is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Abrocitinib Suspension F6?

abrocitinib-suspension-f6 is the generic (nonproprietary) name of Abrocitinib Suspension F6.

What drug class is Abrocitinib Suspension F6 in?

Abrocitinib Suspension F6 belongs to the JAK inhibitor class. See all JAK inhibitor drugs at /class/jak-inhibitor.

What development phase is Abrocitinib Suspension F6 in?

Abrocitinib Suspension F6 is FDA-approved (marketed).

What is Abrocitinib Suspension F6's annual revenue?

Abrocitinib Suspension F6 generated approximately $0.0B in annual revenue.

What does Abrocitinib Suspension F6 target?

Abrocitinib Suspension F6 targets JAK1 and is a JAK inhibitor.

Drug class: All JAK inhibitor drugs
Target: All drugs targeting JAK1
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Moderate to severe atopic dermatitis in adults
Indication: Drugs for Moderate to severe atopic dermatitis in children 12 years of age and older